{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gilbert&page=41&state=Arizona",
    "query": {
      "state": "Arizona",
      "city": "Gilbert",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 991,
    "total_pages": 100,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gilbert&page=42&state=Arizona&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gilbert&page=40&state=Arizona&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T11:48:27.583Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04746963",
      "title": "Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "AXT107 0.1 mg",
          "type": "DRUG"
        },
        {
          "name": "AXT107 0.25 mg",
          "type": "DRUG"
        },
        {
          "name": "AXT107 0.5 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AsclepiX Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2021-02-01",
      "completion_date": "2022-10-01",
      "has_results": true,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-11-22T11:48:27.583Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • St. Petersburg, Florida + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04746963"
    },
    {
      "nct_id": "NCT05703607",
      "title": "A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Shingles",
        "Herpes Zoster Infection",
        "Human"
      ],
      "interventions": [
        {
          "name": "Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 1: PF-07915234: VZV modRNA Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 2: PF-07921188: VZV modRNA Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 3: PF-07921186: VZV modRNA Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shingrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 484,
      "start_date": "2023-01-25",
      "completion_date": "2025-09-23",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-11-22T11:48:27.583Z",
      "location_count": 35,
      "location_summary": "Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05703607"
    },
    {
      "nct_id": "NCT04600336",
      "title": "Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Oxybutynin Chloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 88,
      "start_date": "2021-10-28",
      "completion_date": "2024-03-11",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-11-22T11:48:27.583Z",
      "location_count": 103,
      "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 77 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04600336"
    },
    {
      "nct_id": "NCT04596033",
      "title": "TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Urothelial Carcinoma",
        "Renal Cell Carcinoma",
        "Small-cell Lung Cancer",
        "Cutaneous Squamous Cell Carcinoma",
        "Anal Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "GEN-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-2",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genocea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2020-11-11",
      "completion_date": "2022-06-27",
      "has_results": false,
      "last_update_posted_date": "2022-07-15",
      "last_synced_at": "2026-11-22T11:48:27.583Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04596033"
    },
    {
      "nct_id": "NCT04322604",
      "title": "A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Gastritis",
        "Eosinophilic Duodenitis"
      ],
      "interventions": [
        {
          "name": "lirentelimab (AK002)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Allakos Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 181,
      "start_date": "2020-06-18",
      "completion_date": "2022-01-12",
      "has_results": true,
      "last_update_posted_date": "2024-01-02",
      "last_synced_at": "2026-11-22T11:48:27.583Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04322604"
    },
    {
      "nct_id": "NCT05572515",
      "title": "A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Teclistamab",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 614,
      "start_date": "2023-03-29",
      "completion_date": "2031-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-22T11:48:27.583Z",
      "location_count": 30,
      "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Berkeley, California + 25 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05572515"
    },
    {
      "nct_id": "NCT02186249",
      "title": "Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-02-08",
      "last_synced_at": "2026-11-22T11:48:27.583Z",
      "location_count": 57,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 47 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02186249"
    },
    {
      "nct_id": "NCT03626636",
      "title": "A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Risuteganib",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Allegro Ophthalmics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 42,
      "start_date": "2017-08-01",
      "completion_date": "2019-04-04",
      "has_results": false,
      "last_update_posted_date": "2020-07-08",
      "last_synced_at": "2026-11-22T11:48:27.583Z",
      "location_count": 7,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Beverly Hills, California + 4 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03626636"
    },
    {
      "nct_id": "NCT04228055",
      "title": "Comprehensive Lifestyle Improvement Program for Men With Prostate Cancer2 (CLIPP2)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "CLIPP2",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "40 Years to 80 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2020-08-07",
      "completion_date": "2022-10-31",
      "has_results": false,
      "last_update_posted_date": "2021-08-31",
      "last_synced_at": "2026-11-22T11:48:27.583Z",
      "location_count": 2,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04228055"
    },
    {
      "nct_id": "NCT06747949",
      "title": "A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sjögren's Syndrome"
      ],
      "interventions": [
        {
          "name": "Dazodalibep",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 844,
      "start_date": "2025-02-25",
      "completion_date": "2029-12-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-11-22T11:48:27.583Z",
      "location_count": 31,
      "location_summary": "Avondale, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 27 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06747949"
    }
  ]
}